glp-1 drugs glycemic control mechanism GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Current Insights, Advantages and Challenges

Discovery of a novel series of orally bioavailable and CNS penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) non-competitive antagonists based on a 1,3-disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione core

Both cell lines were cultured in Dulbeccos Modified Eagle Medium (DMEM

Stem Cell Signaling

Peptides are short chains of amino acids, the building blocks of proteins, linked together by peptide bonds

5), epithelial cells in the gut 6 and the central nervous system 7

Eventually, this excess fat spills over into the pancreas, damaging the beta cells responsible for insulin production and leading to prediabetes and, ultimately, type 2 diabetes